SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
SNY

Sanofi (NASDAQ:SNY)

FR · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - General
43.13+0.89 (+2.11%)
 
Market cap
$103B
Insider Score
Members
Health Score
74 Sound
Analyst consensus
Hold
Listed since
Jul 1, 2002
Website
sanofi.com
Insider Score
/ 99
SNY Insider Score

Sanofi has a live Insider Score.

Scored on 1 qualifying trade from 1 insider in the last 90 days.

Unlock SNY’s Insider Score

SNY analyst forecast

SNY ratings mix, last 12 months

Buy Hold Sell

Best analysts covering SNY

No firm covering SNY has enough calls with a finished 1Y holding period to rank yet.

Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.

SNY analyst ratings

FirmPrice targetAction
—Morgan StanleyEqual Weight——Downgraded2026-05-01
—Exane BNP ParibasNeutral——Downgraded2026-04-20
—B of A SecuritiesNeutral——Downgraded2026-02-12
—UBSNeutral——Downgraded2026-01-16
—BarclaysEqual Weight——Downgraded2026-01-06
—GuggenheimNeutral——Downgraded2025-12-09
—JP MorganNeutral——Downgraded2025-12-08
—Morgan StanleyOverweight——Upgraded2025-09-08
—Deutsche BankBuy——Upgraded2025-09-02
—JP MorganOverweight——Upgraded2025-08-08
—Deutsche BankHold——Upgraded2025-01-30
—Argus ResearchBuy——Reiterated2024-07-26
—Argus ResearchBuy——Reiterated2023-03-27
—Deutsche BankHold——Upgraded2022-08-12
—SVB LeerinkOutperform——Upgraded2021-09-27
—Goldman SachsBuy——Upgraded2020-03-11
—Argus ResearchBuy——Reiterated2020-02-19
—JP MorganOverweight——Upgraded2020-01-06
—BarclaysUnderweight——Downgraded2019-12-06
—GuggenheimBuy——Upgraded2019-09-23
—Argus ResearchBuy——Reiterated2018-11-08
—ArgusBuy——Reiterated2018-11-08
—BarclaysEqual Weight——Upgraded2018-11-01
—Bank of AmericaBuy——Upgraded2018-09-10
—B of A SecuritiesBuy——Upgraded2018-09-10
—ArgusBuy——Reiterated2018-08-24
—Argus ResearchBuy——Reiterated2018-08-24
—CitigroupBuy——Upgraded2018-08-10
—BarclaysUnderweight——Downgraded2018-01-23
—BarclaysEqual Weight——Upgraded2017-11-15
—HSBCHold——Upgraded2017-08-30
—BarclaysOverweight——Upgraded2016-05-12
—HSBCHold——Downgraded2016-05-03
—Exane BNP ParibasUnderperform——Downgraded2015-12-10
—Morgan StanleyEqual Weight——Downgraded2015-12-01
—BernsteinMarket Perform——Downgraded2015-11-09
—Bryan GarnierNeutral——Downgraded2015-11-09
—Leerink SwannOutperform——Upgraded2015-03-17
—BarclaysEqual Weight——Downgraded2014-10-29
—B of A SecuritiesNeutral——Downgraded2014-10-29
—Bank of AmericaNeutral——Downgraded2014-10-29
—JefferiesHold——Downgraded2014-10-29
—Deutsche BankHold——Downgraded2014-10-29
—Deutsche BankHold——Downgraded2014-10-28
—CitigroupNeutral——Downgraded2014-01-23
—S&P Capital IQHold——Downgraded2014-01-09
—JP MorganNeutral——Downgraded2014-01-06
—Kepler CheuvreuxBuy——Upgraded2013-11-18
—MirabaudBuy——Upgraded2013-11-15
—Mirabaud SecuritiesBuy——Upgraded2013-11-15
—NatixisBuy——Upgraded2013-10-31
—Leerink SwannMarket Perform——Downgraded2013-10-18
—BarclaysOverweight——Upgraded2013-09-16
—Cowen & Co.Market Perform——Downgraded2013-08-21
—Banco SabadellSell——Downgraded2013-05-03
—Kepler CheuvreuxHold——Downgraded2013-02-08
—BarclaysEqual Weight——Downgraded2013-01-29
—Goldman SachsNeutral——Upgraded2013-01-28
—Standpoint ResearchHold——Downgraded2012-08-03

SNY earnings vs. estimates

QuarterEPS est.EPS actualRevenue est.Revenue actual
2026-01-290.840.89$11.71B$14.34B
2026-04-231.061.10$12.68B$12.94B
2026-07-301.101.21$15.34B$14.06B
2026-10-301.630.00$14.87B$0
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.